Inactive Instrument

Pangaea Oncology, S.A. Share Price BME

Equities

ES0105221008

Biotechnology & Medical Research

Financials

Sales 2024 * 13.8M 14.99M 1.18B Sales 2025 * 14.8M 16.08M 1.27B Capitalization 54.18M 58.87M 4.65B
Net income 2024 * -1M -1.09M -85.82M Net income 2025 * - 0 0 EV / Sales 2024 * 4.32 x
Net Debt 2024 * 5.5M 5.98M 472M Net Debt 2025 * 6.8M 7.39M 584M EV / Sales 2025 * 4.12 x
P/E ratio 2024 *
-36.8 x
P/E ratio 2025 *
-92 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 21.08%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder - 31/12/06
Founder - 31/12/06
Founder - 31/12/06
Members of the board TitleAgeSince
Founder - 31/12/06
Founder - 31/12/06
Founder - 31/12/06
More insiders
Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
More about the company